← All stories
Markets
‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit
Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.
Covered by 1 outlet
All coverage · 1 article